Introduction of Hongri Pharmaceutical Company:
1, Tianjin Hongri Pharmaceutical Co., Ltd. was established on 1996, and is the first batch of enterprises listed on the Growth Enterprise Market in China. Up to now, it has developed into a high-tech medical and health industrial cluster integrating investment and financing, production, R&D and sales, spanning many fields such as finished drugs, traditional Chinese medicine industrial clusters, pharmaceutical excipients and raw materials, medical devices and so on. , more than 60 companies, more than 6000 employees. In recent years, the company has won many honors such as national high-tech enterprises and national technological innovation demonstration enterprises, and has become one of the top 100 pharmaceutical industries in China. In 20 19, the main business income was 5 billion yuan, the total assets were 8.454 billion yuan, and the tax payment was 690 million yuan.
2. Scientific and technological innovation and industrialization of achievements are the driving forces for the continuous development of Hongri Pharmaceutical. Hongri Pharmaceutical Co., Ltd. relies on two established national technical platforms, namely the National Enterprise Technology Center and the National and Local Joint Engineering Research Center for Key Technologies of Chinese Medicine Formula Granules, and cooperates with famous academicians such as Zhong Nanshan and Zhang Boli to continuously carry out innovative research on key technologies such as anti-tumor, Xuebijing treatment in COVID-19 and secondary development of Chinese patent medicines.
3. With the focus on solving critical problems, the value pursuit of saving lives and reducing mortality, and the innovative direction of creating killer product groups, we have developed world-class stem cell therapy technology, innovative drugs for critical sepsis and small anti-tumor drugs. At present, there are five new drugs 1 such as KB, PD-L 1, more than 40 research projects, nearly 400 effective patents, and dozens of new products will be listed one after another.
4. Xuebijing injection, a product owned by Hongri Pharmaceutical with independent intellectual property rights, fills the gap in the field of international sepsis treatment. In 20 19, the research paper was published in the top international journal Critical Care Medicine. Xuebijing effectively reduced the mortality rate of severe pneumonia by 8.8%, and was called "a model of Chinese medicine going abroad" by Academician Zhong Nanshan.